Wall Street expects a year-over-year increase in earnings on higher revenues when Clearside Biomedical, Inc. (CLSD) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Collegium Pharmaceutical (COLL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better t ...

Crocs (CROX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better than expectations. ...

Company Overview - ZipRecruiter, Inc. (ZIP) is expected to report a year-over-year decline in earnings, with a projected loss of $0.17 per share, representing a change of -142.9% [3][12] - Revenues for the upcoming quarter are anticipated to be $108.17 million, down 11.5% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on May 8, 2025, and could influence stock movement based on whether the results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised 10.87% higher over the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model indicates that the Most Accurate Estimate for ZipRecruiter aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11] - Despite a Zacks Rank of 2 (Buy), the combination of a 0% Earnings ESP makes it challenging to predict an earnings beat conclusively [11] Historical Performance - In the last reported quarter, ZipRecruiter met the expected loss of $0.11 per share, resulting in no surprise [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Context - In comparison, UL Solutions Inc. (ULS) is expected to post earnings of $0.32 per share for the same quarter, reflecting a year-over-year increase of +14.3% and revenues of $703.87 million, up 5.1% from the previous year [17]

Core Viewpoint - Wave Life Sciences (WVE) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended March 2025, which could significantly influence its stock price based on actual results compared to estimates [1][2]. Company Summary - The consensus estimate indicates a quarterly loss of $0.27 per share for Wave Life Sciences, reflecting a year-over-year change of -12.5%. Revenues are projected to be $13.97 million, representing an 11.4% increase from the previous year [3]. - Over the last 30 days, the consensus EPS estimate has been revised 0.43% lower, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Wave Life Sciences is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.89%. The company currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat [10][11]. Earnings Surprise History - In the last reported quarter, Wave Life Sciences was expected to post a loss of $0.17 per share but instead reported earnings of $0.17, resulting in a surprise of +200%. However, the company has only beaten consensus EPS estimates once in the last four quarters [12][13]. Industry Context - Rhythm Pharmaceuticals, another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.69 per share for the same quarter, indicating a year-over-year change of +70.6%. Its revenues are expected to be $40.18 million, up 54.7% from the previous year [17]. - The consensus EPS estimate for Rhythm Pharmaceuticals has been revised 0.7% lower in the last 30 days, leading to an Earnings ESP of -12.84% and a Zacks Rank of 3, complicating predictions for an earnings beat [18].

Group 1: Earnings Expectations for Akamai Technologies - Wall Street anticipates a year-over-year decline in earnings for Akamai Technologies, with expected earnings of $1.58 per share, reflecting a -3.7% change, while revenues are projected to be $1.01 billion, up 2.2% from the previous year [3][12] - The earnings report is scheduled for May 8, 2025, and the stock may rise if results exceed expectations, but could decline if they fall short [2][14] - The consensus EPS estimate has been revised 0.14% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4][10] Group 2: Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +0.07% for Akamai Technologies, suggesting a likelihood of beating the consensus EPS estimate [11][10] - Historical performance indicates that Akamai has beaten consensus EPS estimates three out of the last four quarters, with a notable surprise of +9.21% in the last reported quarter [12][13] Group 3: Comparison with Industry Peers - Zillow, another player in the Zacks Internet - Services industry, is expected to report earnings of $0.43 per share, a +19.4% year-over-year change, with revenues of $588.55 million, up 11.3% [17] - Zillow's consensus EPS estimate has remained unchanged, but it has a negative Earnings ESP of -8.67% and a Zacks Rank of 4 (Sell), making it difficult to predict an earnings beat [18]

Core Viewpoint - Akebia Therapeutics (AKBA) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with a consensus outlook suggesting a quarterly loss of $0.03 per share, reflecting a 66.7% improvement from the previous year, and revenues expected to reach $45.21 million, a 38.6% increase from the same quarter last year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, while a miss could lead to a decline in stock value [2]. - The consensus EPS estimate has been revised 30% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +45.46% for Akebia Therapeutics, suggesting a strong likelihood of beating the consensus EPS estimate [11]. - The company currently holds a Zacks Rank of 3, which, when combined with the positive Earnings ESP, indicates a favorable outlook for the upcoming earnings report [11]. Historical Performance - In the last reported quarter, Akebia Therapeutics was expected to post a loss of $0.08 per share but actually reported a loss of $0.10, resulting in a surprise of -25% [12]. - Over the past four quarters, the company has only surpassed consensus EPS estimates once [13]. Industry Comparison - Another player in the Zacks Medical - Drugs industry, Heron Therapeutics (HRTX), is expected to report a loss of $0.01 per share for the same quarter, reflecting a year-over-year change of +50%, with revenues projected at $37.08 million, a 7% increase from the previous year [17]. - Heron Therapeutics has seen a 50% upward revision in its consensus EPS estimate over the last 30 days and holds an Earnings ESP of 100.00%, indicating a strong likelihood of beating the consensus EPS estimate [18].

Company Overview - Astrana Health, Inc. (ASTH) is expected to report a year-over-year decline in earnings of 25.8%, with an estimated EPS of $0.23 for the quarter ended March 2025 [3][12] - Revenue is projected to be $635.17 million, reflecting a significant increase of 57.1% compared to the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on May 8, 2025, and could lead to stock price movements depending on whether the results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised 6.67% higher in the last 30 days, indicating a more optimistic outlook from analysts [4][10] Earnings Surprise Prediction - The Zacks Earnings ESP for Astrana Health is +13.04%, suggesting a higher likelihood of beating the consensus EPS estimate [11] - The company currently holds a Zacks Rank of 3 (Hold), which indicates a moderate outlook [11] Historical Performance - In the last reported quarter, Astrana Health was expected to post earnings of $0.09 per share but instead reported a loss of $0.15, resulting in a surprise of -266.67% [12] - Over the past four quarters, the company has only beaten consensus EPS estimates once [13] Industry Context - In the Zacks Medical - Outpatient and Home Healthcare industry, Elanco Animal Health Incorporated (ELAN) is also expected to report earnings, with an EPS estimate of $0.31, reflecting a year-over-year decline of 8.8% [17] - Elanco's revenue is anticipated to be $1.17 billion, down 3.1% from the previous year [17]

Group 1: Cibus Earnings Expectations - The market anticipates Cibus (CBUS) to report a year-over-year increase in earnings driven by higher revenues for the quarter ended March 2025 [1] - The consensus EPS estimate for Cibus is a loss of $0.70 per share, reflecting a year-over-year change of +37.5%, with expected revenues of $1.18 million, up 114.6% from the previous year [3] - The consensus EPS estimate has been revised 1.49% lower in the last 30 days, indicating a reassessment by analysts [4] Group 2: Earnings Surprise Prediction - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate predictions [6] - Cibus has an Earnings ESP of -5.04%, indicating a bearish outlook from analysts regarding the company's earnings prospects [10] - The stock currently holds a Zacks Rank of 2, making it challenging to predict a consensus EPS beat [11] Group 3: Historical Performance and Industry Comparison - Cibus has only beaten consensus EPS estimates once in the last four quarters, with a recent surprise of -14.47% when it reported a loss of $0.87 per share against an expected loss of $0.76 [12][13] - Corteva, Inc. (CTVA), another player in the agriculture operations industry, is expected to post earnings of $0.87 per share, indicating a year-over-year change of -2.3%, with revenues projected at $4.51 billion, up 0.4% [17] - Corteva's consensus EPS estimate has been revised 1.4% higher, resulting in a positive Earnings ESP of 0.19%, suggesting a likely beat against the consensus EPS estimate [18]

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better than ...